The Colombian innovator turning air pollution into raw materials
Against this backdrop, Colombian entrepreneur Mariana Pérez has developed a solution that tackles both environmental and health crises – earning her a place among the top ten innovators in the Young Inventors Prize 2025, awarded by the European Patent Office (EPO).
At just 27, Pérez is the founder of Ecol-Air, a startup behind a technology that captures not only carbon dioxide but also nitrogen dioxide and sulphur dioxide – gases linked to respiratory illness. Unlike traditional carbon-capture devices, her system mimics the human respiratory system, using artificial 'bronchioles' and 'alveoli' to absorb pollutants from the air.
'My invention is just like a giant vacuum that captures a volume of air and puts it through this system and breaks down all the contaminants into a tank,' she explains. Installed on chimneys or as free-standing air purification stations, the machine treats polluted air and processes the toxins into biodegradable polymers – materials that can be repurposed into sustainable packaging or industrial components like tiles and bags.
'We can transform the pollutants and contaminants into raw materials that can be used,' says Pérez, 'I decided to create this machine because people ignore that air is as important as water.'
Pérez's interest in air quality began when she was just eight years old. 'I remember watching rain wash residue off my dad's car and wondering where all that black dust went,' she recalls. That childhood curiosity grew into a passion for science, leading her to participate in school science fairs and eventually develop early prototypes of the machine that would inspire Ecol-Air.
'There were moments in my journey when I doubted myself,' she admits. 'But I believe all scientists need to realise that, while we can create incredible solutions for the planet, health and people, scaling our projects and turning them into businesses is what gives our inventions a real future. We can't stop at just having an idea; we need to develop it further.'
After facing initial scepticism from manufacturers, Pérez offered to install her units for free in large factories to demonstrate their effectiveness. Sumicol was the first to adopt the system commercially, followed by Incolmotos Yamaha. In 2021, the first air treatment plant using her technology opened in Girardota, processing 70 tonnes of air daily with an 82% efficiency rate, according to company data.
Now living in New York, Pérez is preparing for global expansion. 'Right now I'm focused on a global expansion because all the world needs to purify air,' she says. 'We are focused on trying to put our machine in large industries. Our invention is in the Commercial Readiness Level9 stage, meaning that it is fully functional, fully operative and, of course, tested, and ready to be adopted by the market.'
With her innovation, Pérez is directly addressing multiple UN Sustainable Development Goals, including SDG 3 (Good Health and Well-being), SDG 11 (Sustainable Cities and Communities), and SDG 13 (Climate Action). As one of the EPO's 2025 Tomorrow Shapers, she's helping reshape how we think about pollution: not just as a problem to contain, but as a resource to transform.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Euronews
3 days ago
- Euronews
Rich countries pay more for medicines, but cost burden is far lower
Wealthy countries may pay steep prices for medicines, but once their purchasing power is factored in, they actually benefit from some of the lowest costs in the world, a new study has found. The analysis of 549 essential medicines across 72 markets worldwide reveals major disparities in affordability between wealthier and poorer countries – even though rich countries often pay higher list prices. While poorer nations often have lower list prices, people in those countries tend to shoulder a far greater financial burden, according to the study, which was published in the journal JAMA Health Forum. In parts of Africa and Southeast Asia, critical medicines can cost the lowest-income earners several weeks' worth of wages if they have to pay out of pocket. The 549 drugs included in the study were sourced from the World Health Organization's (WHO) essential medicines list, which tallies the most important medicines for health systems to function. They include everything from over-the-counter painkillers to antibiotics, anaesthetics, and mental health drugs. No country stocked every drug, with availability ranging from 438 medicines in Germany to 225 in Kuwait. Across the 33 European countries included in the study, the average was 367 medicines. The study found that treatments for mental and behavioural disorders and cardiovascular disease tended to be the most expensive, while drugs for hepatitis B and C were generally the cheapest. European countries spent the most on essential medicines – $2 billion (€1.74 billion) overall and $192 (€167) per capita. At the other end of the spectrum, the Americas spent $1 billion (€868 million) overall and Southeast Asia spent $7 (€6) per capita in 2022. However, a medicine's list price – the sticker price set by a drugmaker before any discounts, subsidies, or insurance are taken into account – can be misleading. Cost of living and the government's role in setting drug prices vary around the world. To better reflect affordability, researchers used Germany as a benchmark and adjusted prices for local purchasing power. They found that medicine prices in Lebanon were roughly one-fifth of German prices, while in Argentina, prices were nearly six times as high as in Germany. In Pakistan, for example, drug prices may be lower on paper, but once purchasing power is factored in, they're about the same as in Germany. And in the United States, prices reached three times the German level. Meanwhile in India, minimum-wage earners would need about 10 days of work to afford a monthlong dose of tenofovir disoproxil, which treats chronic hepatitis B and helps prevent and treat HIV/AIDS. For the chemotherapy drug paclitaxel, minimum-wage labourers in lower-income countries would need to work for nearly six weeks to pay for a monthlong course of the treatment. 'Some poorer countries face a higher burden of medication costs, even if the price for the same medicine is lower compared to richer countries,' the researchers said.
Euronews
5 days ago
- Euronews
What's driving the rise in STIs among older Europeans?
Sexually transmitted infections (STIs) are not exclusively a problem of young people. Young adults in their 20s and 30s usually top the charts for common bacterial STIs such as gonorrhoea, chlamydia, and syphilis – but rates among those in midlife and beyond are climbing in parts of Europe. According to a 2024 report from the United Kingdom's Health Security Agency, there has been a 'steady increase' in STI diagnoses among people aged 65 years and older in recent years. There were 1,649 gonorrhoea, chlamydia, and syphilis diagnoses among older Britons in 2023, up from 576 in 2014 – a nearly threefold increase. In France, meanwhile, gonorrhoea and syphilis incidence rose more sharply in people over 50 than in younger adults between 2021 and 2023. Chlamydia also rose among men over 50, according to the French public health agency. In Denmark, men aged 50 and above saw some of the largest increases in gonorrhea cases from 2022 to 2023. And across the European Union, people aged 45 and older accounted for 32 per cent of all syphilis cases in 2023. Infections like gonorrhoea, chlamydia, and syphilis are bacterial STIs which can be cured with antibiotics, unlike herpes and HIV, which are lifelong viral infections, according to the World Health Organization (WHO). Why are STI cases rising among older adults? The uptick does not appear to be slowing down. According to a study from the University of Manchester in the UK, the number of STI diagnoses is expected to continue rising among older people in England through at least 2040. The study authors said it is not clear what's driving this trend, but that the ageing population and growing number of diagnoses could translate to rising treatment costs for STIs in the coming years. Other experts say that because women often outlive men, they may look for new partners later in life. Meanwhile, sexual performance drugs such as Viagra have given some older men a chance to re-engage in sex later in life. Older adults may also have little knowledge about how different types of STIs are transmitted or how to prevent them from spreading, particularly given they are safe from the risk of unintended pregnancies, one small study concluded. Destigmatising STIs in older adults Experts say both health care professionals and the public should consider the sexual health needs of older people. 'There is a common misconception that older adults do not have sex, they don't want to have sex, or they cannot have sex,' said Matthew Smith, a Texas A&M professor focused on older adults' health at Texas A&M University in the United States. 'And unfortunately, those misconceptions can lead to a lack of communication, a lack of speaking with health care providers, a lack of talking to partners about safer sex practices like using condoms or sharing partners,' he added. Whether they are widowed, divorced, or simply seeking companionship, Smith said older adults should ask potential new partners about their sexual history, use of contraception, and STI testing – topics he said are 'not necessarily something routine among older adults'. Smith said doctors should also discuss sexual health with their patients, given 'we are sexual beings across the life course'. 'It's something that oftentimes is shied away from, in conversation,' he said. 'There's a little bit of stigma based on [their] age, where not everybody likes to envision that age group engaging in these behaviours'.
Euronews
7 days ago
- Euronews
Cats develop dementia similarly to humans, study finds
Cats develop dementia similarly to humans, according to new research that scientists say could help them explore new treatments for the disease. Researchers from the University of Edinburgh carried out post-mortem examinations on the brains of 25 cats, all of which had exhibited symptoms of feline dementia. Symptoms can include confusion, disrupted sleep cycles, more frequent vocalisation, and missing the litter box, according to the study, which was published in the European Journal of Neuroscience. Using powerful microscopy images, the researchers found an accumulation of amyloid-beta plaques in the cats' brains. These plaques are a toxic protein that affect the brain's ability to communicate messages and remember things, and they are characteristic of Alzheimer's disease. "Our findings highlight the striking similarities between feline dementia and Alzheimer's disease in people," said Robert McGeachan, the study's lead author and a lecturer at the University of Edinburgh's veterinary school. "Because cats naturally develop these brain changes, they may also offer a more accurate model of the disease than traditional laboratory animals, ultimately benefiting both species and their caregivers,' McGeachan added. Typically, scientists study dementia with genetically modified rodents, which don't naturally develop the syndrome. Feline dementia, however, is the "perfect natural model for Alzheimer's," said Danièlle Gunn-Moore, a feline medicine professor at the school. The development could help lead to a more advanced understanding of how the disease progresses, and the creation of new treatments in the future, the researchers said. "Feline dementia is so distressing for the cat and for its person," Gunn-Moore said. "It is by undertaking studies like this that we will understand how best to treat them". Alzheimer's is the most common form of dementia, according to the World Health Organization (WHO), contributing to an estimated 60 per cent to 70 per cent of cases. While there is currently no known cure, medications can help some people manage symptoms.
